In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM- and complex mutant TEM-producing clinical strains of Escherichia coli

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 5, 2011, Pages 1052-1056

  Robin, Frédéric ^a,b,c   Krebs, Marion ^a,b,c   Delmas, Julien ^a,b,c   Gibold, Lucie ^a,b,c   Mirande, Caroline ^a,b,c   Bonnet, Richard ^a,b,c  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c CEMAGREF   (France)

Author keywords

lactamase inhibitors; lactamases; Antibiotics; Bactericidal activity; Resistance

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BROTH DILUTION; DISK DIFFUSION; ESCHERICHIA COLI; INOCULATION; MICROBIAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MUTANT PROTEINS; PENICILLANIC ACID; PIPERACILLIN;

EID: 79954594742     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr045     Document Type: Article

References (10)

1. Knothe H, Shah P, Krcmery V et al. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11: 315-7.
2. Chaibi EB, Sirot D, Paul G et al. Inhibitor-resistant TEM β-lactamases: phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother 1999; 43: 447-58.
3. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.2_101220.pdf (5 January 2011, date last accessed).
4. Comité de l'Antibiogramme de la Société Française de Microbiologie. Recommandations 2010. http://www.sfm-microbiologie.org/UserFiles/file/casfm_2010.pdf (5 January 2011, date last accessed).
5. Sirot D, Recule C, Chaibi EB et al. A complex mutant of TEM-1 β-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate. Antimicrob Agents Chemother 1997; 41: 1322-5.
6. Burgess DS, Waldrep T. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing. Clin Ther 2002; 24: 1090-104.
7. Tam VH, Ledesma KR, Chang KT et al. Killing of Escherichia coli by β-lactams at different inocula. Diagn Microbiol Infect Dis 2009; 64: 166-71.
8. Craig WA, Bhavnani SM, Ambrose PG. The inoculum effect: fact or artifact? Diagn Microbiol Infect Dis 2004; 50: 229-30.
9. Rice LB, Yao JD, Klimm K et al. Efficacy of different β-lactams against an extended-spectrum β-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrob Agents Chemother 1991; 35: 1243-4.
10. Leflon-Guibout V, Ternat G, Heym B et al. Exposure to co-amoxiclav as a risk factor for co-amoxiclav-resistant Escherichia coli urinary tract infection. J Antimicrob Chemother 2002; 49: 367-71.